Design Therapeautics, Inc. (DSGN) Live Share Price, Invest From India

Design Therapeautics, Inc. Stock Performance

as on January 28, 2026 at 9:35 pm IST

Day's Low
Day's High
$10.24
Day's Price Range
$10.63
$10.36
1.16%
Downside
2.61%
Upside
52 Week's Low
52 Week's High
$2.60
52-Week Price Range
$10.97
$10.36
74.90%
Downside
5.89%
Upside

Design Therapeautics, Inc. share price movements today

Previous Close: $10.59
Open: $10.59
Volume: 52.3K
Day's Low - High: $10.24 - $10.63
52 Week Low - High: $2.60 - $10.97

Design Therapeautics, Inc. Historical Returns

1 Month Return: + 9.97 %
3 Month Return: + 58.53 %
1 Year Return: + 111.38 %
3 Year Return: + 28.05 %
5 Year Return: 0 %

Design Therapeautics, Inc. Stock Fundamentals & Key Indicators

Check Design Therapeautics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$595.8M

EPS (TTM)

-1.302

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-77.0M

Revenue (TTM)

33.0K

Profit Margin

0.00%

Return On Equity TTM

-29.83%

Design Therapeautics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Design Therapeautics, Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Design Therapeautics, Inc.	HOLD	$595.8M	NA	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$47.7B	129.26%	1246.03	1.36%
Vertex Pharmaceuticals Incorporated	BUY	$122.3B	106.13%	33.56	31.35%
Beone Medicines Ltd	NA	$37.4B	NA	662.33	1.38%
Regeneron Pharmaceuticals, Inc.	BUY	$80.8B	52.34%	18.28	32.13%

Stock Returns calculator for Design Therapeautics, Inc. Stock including INR - Dollar returns

The Design Therapeautics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Design Therapeautics, Inc. investment value today

Current value as on today

₹2,12,761

Returns

₹1,12,761

(+112.76%)

Returns from Design Therapeautics, Inc. Stock

₹1,06,786 (+106.79%)

Dollar Returns*

₹5,974 (+5.97%)

Analyst Recommendation on Design Therapeautics, Inc. Stock

Based on 8 analysts

HOLD

0.00%

Buy

62.50%

Hold

37.50%

Sell

Based on 8 analysts, 62.5% of analysts recommend a 'HOLD' rating for Design Therapeautics, Inc.. Average target price of $14.4

Design Therapeautics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Design Therapeautics, Inc..

What analysts predicted

28.06%UPSIDE

Target Price

$14.4

Current Price

$10.36

Analyzed by

8 Analysts

Target

$14.40

Design Therapeautics, Inc. target price $14.4, a slight upside of 28.06% compared to current price of $10.36. According to 8 analysts rating.

Design Therapeautics, Inc. Stock’s Investor Sentiment and Interest

Search interest for Design Therapeautics, Inc. Stock has decreased by -25% in the last 30 days, reflecting a downward trend in search activity.

Time period: December 29, 2025 to January 28, 2026

Change:-25% versus previous 30 day period

Design Therapeautics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Total Revenue	-	-	0	-	-	-	0	-	-	-
Gross Profit	0	0	0	0	0	0	0	0	0	-14
Operating Income	-22	-18	-15	-14	-15	-16	-16	-20	-21	-19
EBITDA	-22	-18	-14	-14	-14	-16	-16	-20	-18	-16
Interest Expense	-	-	0	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-19	-15	-11	-11	-11	-13	-13	-17	-19	-16
Income Tax Expense	0	0	2	0	-	-	-	-	-	-
Net Income	-19	-15	-11	-11	-11	-13	-13	-17	-19	-16
Net Profit Margin	0.00%	0.00%	-1413.13%	0.00%	0.00%	0.00%	-2321.60%	0.00%	0.00%	0.00%

Design Therapeautics, Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	0	0	-	-	-	-
Gross Profit	0	0	0	0	0	0
Operating Income	-1	-8	-35	-67	-78	-62
EBITDA	-1	-8	-35	-67	-66	-48
Interest Expense	-	-	0	4	-	-
Depreciation	-	0	0	0	0	0
Income Before Tax	-2	-8	-35	-63	-66	-49
Income Tax Expense	0	0	0	-4	0	-
Net Income	-2	-8	-35	-58	-66	-49
Net Profit Margin	-245.44%	-3663716.81%	0.00%	0.00%	0.00%	0.00%

Design Therapeautics, Inc. Quarterly Cash Flow

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Net Income	-15	-11	-11	-11	-13	-13	-17	-19	-16
Operating Cash Flow	-14	-12	-12	-11	-9	-9	-16	-14	-11
Investing Cash Flow	15	5	20	27	-5	1	7	20	6
Financing Cash Flow	0	0	0	0	0	0	0	0	0
Change in Cash	0	-6	8	16	-15	-7	-8	6	-4

Design Therapeautics, Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-8	-35	-63	-66	-49
Operating Cash Flow	-8	-29	-51	-58	-43
Investing Cash Flow	-33	-53	-220	52	43
Financing Cash Flow	44	379	0	0	0
Change in Cash	2	296	-272	-5	1

Global Institutional Holdings in Design Therapeautics, Inc.

Funds	Holdings
Kynam Capital Management, LP	1.81%
FMR Inc	1.67%
Dimensional Fund Advisors, Inc.	0.55%
TANG CAPITAL MANAGEMENT LLC	3.13%
Vanguard Group Inc	2.58%

See all

Insights on Design Therapeautics, Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 7 days, DSGN stock has moved up by 10.9%
POSITIVE IMPACT
Best in 1 Year
In the last 1 year, DSGN has outperformed top 5 stocks with highest market-cap in its industry
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 29.4% return, outperforming this stock by 1.3%

About Design Therapeautics, Inc.

Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.

Organisation	Design Therapeautics, Inc.
Headquarters	6005 Hidden Valley Road, Carlsbad, CA, United States, 92011
Industry	Healthcare
CEO	Mr. Pratik Shah Ph.D.
E-voting on shares	Click here to vote

Key Management of Design Therapeautics, Inc.

Name	Title
Mr. Jim Kerr	Chief of Manufacturing & Product Development
Dr. Chengzhi Zhang Ph.D.	Chief Chemist
Dr. Chris M. Storgard M.D.	Chief Medical Officer
Mr. Pratik Shah Ph.D.	Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson
Dr. Sean Jeffries Ph.D.	Chief Operating Officer
Mr. Mustapha Parekh	General Counsel
Dr. Tadimeti S. Rao Ph.D.	Chief Scientific Officer
Dr. Aseem Z. Ansari Ph.D.	Co-Founder & Scientific Advisor
Ms. Julie D. Burgess CPA	Chief Accounting Officer
Mr. Doane Chilcoat Ph.D.	Chief Technology Officer

FAQs

What is Design Therapeautics, Inc. share price today?

Design Therapeautics, Inc. share price today is $10.36 as on January 28, 2026 at 9:35 pm IST. Design Therapeautics, Inc. share today touched a day high of $10.63 and a low of $10.24.

What is the 52 week high and 52 week low for Design Therapeautics, Inc. share?

Design Therapeautics, Inc. share touched a 52 week high of $10.97 on January 27, 2026 and a 52 week low of $2.6 on April 11, 2025. Design Therapeautics, Inc. stock price today i.e. January 28, 2026 at 9:35 pm IST is trending at $10.36,which is 5.56% down from its 52 week high and 298.46% up from its 52 week low.

What is Design Therapeautics, Inc.'s market capitalisation today?

Design Therapeautics, Inc. market capitalisation is $0.00T as on January 28, 2026 at 9:35 pm IST.

How to invest in Design Therapeautics, Inc. Stock (DSGN) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Design Therapeautics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Design Therapeautics, Inc. Shares that will get you 0.1448 shares as per Design Therapeautics, Inc. share price of $10.36 per share as on January 28, 2026 at 9:35 pm IST.

What is the minimum amount required to buy Design Therapeautics, Inc. Stock (DSGN) from India?

Indian investors can start investing in Design Therapeautics, Inc. (DSGN) shares with as little as ₹91.762 or $1 (as of January 28, 2026 at 9:37 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹917.62 in Design Therapeautics, Inc. stock (as per the Rupee-Dollar exchange rate as on January 28, 2026 at 9:37 pm IST). Based on Design Therapeautics, Inc. share’s latest price of $10.36 as on January 28, 2026 at 9:35 pm IST, you will get 0.9653 shares of Design Therapeautics, Inc.. Learn more about fractional shares .